Synergy's clinical success fuels the M&A rumor mill

A Phase III victory for Synergy Pharmaceuticals' ($SGYP) constipation drug has made the company an attractive takeout target, analysts say, with the acquisitive Valeant Pharmaceuticals ($VRX) a potential suitor. As Cantor's Irina Rivkind Koffler wrote in a research note, plecanatide's success in treating chronic idiopathic constipation sets the stage for a likely FDA approval, and Valeant, already at work in the gastrointestinal space, may see a lucrative opportunity to compete with the likes of Ironwood Pharmaceuticals ($IRWD) and Allergan ($AGN). More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.